Gyre Therapeutics (NASDAQ:GYRE) Shares Down 8.3%

Gyre Therapeutics, Inc. (NASDAQ:GYRE) fell 8.3% during trading on Wednesday . The company traded as low as $9.08 and last traded at $9.10. 31,271 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 73,932 shares. The stock had previously closed at $9.92.

Gyre Therapeutics Stock Performance

The stock’s 50 day simple moving average is $12.93 and its two-hundred day simple moving average is $16.93.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Thursday, May 9th. The company reported $0.04 earnings per share for the quarter. The business had revenue of $27.17 million for the quarter. Equities analysts forecast that Gyre Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, Director Nassim Usman sold 20,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $14.13, for a total value of $282,600.00. Following the sale, the director now directly owns 1,636 shares in the company, valued at $23,116.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.92% of the stock is currently owned by insiders.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.